MATTHEW TRZESNIOWSKI: Open Payments
NPI 1487933503 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,027 in 46 payments from 12 companies in 2025. Trend: 2023 $966 · 2024 $926 · 2025 $1,027
Food & beverage: $1,027
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $226 |
| Abbott Laboratories | 4 | $221 |
| Lilly USA, LLC | 7 | $153 |
| Astellas Pharma US Inc | 5 | $114 |
| AstraZeneca Pharmaceuticals LP | 4 | $65 |
| Viatris Specialty LLC | 3 | $64 |
| Novo Nordisk Inc | 2 | $46 |
| Amgen Inc. | 2 | $38 |
| Currax Pharmaceuticals LLC | 2 | $32 |
| GlaxoSmithKline, LLC. | 1 | $26 |
Products named: FREESTYLE LIBRE 3, VRAYLAR, MOUNJARO, Veozah, QULIPTA, YUPELRI, FARXIGA, JOT DX.
Industry payments across PA — which companies pay providers there.
